Fat-derived stem cells safe and feasible for SPMS, clinical trial

I have secondary progressive multiple sclerosis (SPMS) and am delighted with any advance in treating that form of the disease. This week, I am pleased that a clinical trial shows that fat-derived stem cells are a safe and feasible treatment for people with SPMS. The study, Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of … Continue reading Fat-derived stem cells safe and feasible for SPMS, clinical trial

Ocrevus: Counting Down to Expected FDA Approval

There is now less than a month until the U.S. Food and Drug Administration (FDA) is expected to approve Ocrevus, generic name ocrelizumab, for use as a therapy for multiple sclerosis. Clinical trials have shown Genentech’s drug to be a promising therapy for relapsing MS and, significantly, the primary progressive form of the disease for … Continue reading Ocrevus: Counting Down to Expected FDA Approval